Media Articles Related to Namenda (Memantine)
Study demonstrated clinically meaningful and statistically significant improvement of agitation in patients with Alzheimer's disease
Source: Anxiety / Stress News From Medical News Today [2014.10.16]
Avanir Pharmaceuticals, Inc. has announced that results from the Phase II study evaluating AVP-923 for the treatment of agitation in patients with Alzheimer's disease were presented at the 2014...
Laying siege to beta-amyloid, the key protein in Alzheimer's disease
Source: Huntingtons Disease News From Medical News Today [2014.10.06]
The peptide - a small protein - beta-amyloid is strongly associated with Alzheimer's disease; however, researchers are still looking for unequivocal proof that this peptide is the causal agent of the...
Memory and Alzheimer's disease
Source: Schizophrenia News From Medical News Today [2014.09.03]
Research by Dr. Sylvain Williams shows that the flow of activity in the hippocampus, a brain region essential for memory, is actually bidirectional, rather than just unidirectionalA study just...
Protein implicated in Alzheimer's disease has important treatment potential in genetic form of epilepsy
Source: Epilepsy News From Medical News Today [2014.08.16]
Researchers at the Gladstone Institutes have shown that reducing brain levels of the protein tau effectively blocks the development of disease in a mouse model of Dravet syndrome, a severe...
Source: MedicineNet First Aid Specialty [2014.08.05]
Title: Alzheimer's Disease
Category: Symptoms and Signs
Created: 8/5/2014 2:43:00 PM
Last Editorial Review: 8/5/2014 2:43:52 PM
Published Studies Related to Namenda (Memantine)
The sustained mood-stabilizing effect of memantine in the management of treatment resistant bipolar disorders: Findings from a 12-month naturalistic trial. [2012.01]
BACKGROUND: We have recently provided preliminary clinical observations indicating that memantine, as augmenting agent, was associated with a meaningful antimanic and mood-stabilizing effect in treatment-resistant bipolar disorders. To further investigate the therapeutic and prophylactic action of the drug we administered memantine, as augmenting agent, to 40 treatment-resistant bipolar disorder patients, monitored and evaluated for 12months... CONCLUSIONS: The results confirm our previous observations and strongly suggest that memantine, as augmenting agent, was associated with a clinically substantial antimanic and sustained mood-stabilizing effect, with excellent safety and tolerability profile. Copyright (c) 2011 Elsevier B.V. All rights reserved.
Donepezil and memantine for moderate-to-severe Alzheimer's disease. 
disease... CONCLUSIONS: In patients with moderate or severe Alzheimer's disease, continued
Memantine and functional communication in Alzheimer's disease: results of a
12-week, international, randomized clinical trial. 
Post hoc analyses suggest that memantine treatment may provide
communication-related benefits in patients with Alzheimer's disease (AD). In this
12-week, international, randomized, double-blind, placebo-controlled trial of
memantine (10 mg bid), the functional communication abilities of patients with AD
(MMSE range: 10-19) were assessed using the Functional Linguistic Communication
Inventory (FLCI; primary measure)...
A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence. [2011.12.01]
BACKGROUND: Preclinical findings suggest that the inhibition of NMDA glutamatergic neurotransmission may have beneficial effects in the treatment of opioid dependence. AIMS: We hypothesized that memantine, a low-potency, uncompetitive NMDA receptor antagonist, would be safe and effective when used as an adjunct to oral naltrexone in the treatment of opioid dependence, particularly in preventing relapse to opiate use in detoxified individuals... CONCLUSION: Thus, the efficacy of memantine 30 or 60 mg/day as an adjunct to oral naltrexone for the treatment of opiate dependence was not supported. Copyright (c) 2011 Elsevier Ireland Ltd. All rights reserved.
Alzheimer's disease - input of vitamin D with mEmantine assay (AD-IDEA trial): study protocol for a randomized controlled trial. [2011.10.20]
ABSTRACT: BACKGROUND: Current treatments for Alzheimer's disease and related disorders (ADRD) are symptomatic and can only temporarily slow down ADRD...
Clinical Trials Related to Namenda (Memantine)
Memantine and Intensive Speech-Language Therapy in Aphasia [Completed]
- Aphasia, the loss or impairment of language caused by brain damage, is one of the most
devastating cognitive impairments of stroke. Aphasia can be treated with combination of
speech-language therapy and drugs. Conventional speech-language therapy in chronic
aphasic subjects is of little help and several drugs have been studied with limited
success. Therefore other therapeutic strategies are warranted.
- Recent data suggest that drugs (memantine) acting on the brain chemical glutamate may
help the recovery of cognitive deficits, included language, in subjects with vascular
dementia. The present study examines the safety profile and efficacy of memantine paired
with intensive language therapy in subjects with stroke-related chronic aphasia (more
than 1 yr. of evolution).
Effect of Namenda on Short Term Memory and Attention in Patients With Mild to Moderate Traumatic Brain Injury [Recruiting]
The purpose of this study is to determine whether memantine (Namenda) improves memory and
attention in patients with mild to moderate traumatic brain injury.
A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease [Recruiting]
The primary study hypothesis is that compared with placebo, alpha-tocopherol, memantine
(Namenda), or the combination will significantly delay clinical progression in mild to
moderately demented patients with Alzheimer's disease.
Efficacy and Safety of the Use of Memantine for Preserving Cognition in Adult Patients With Epilepsy [Not yet recruiting]
People with epilepsy often experience problems with their memories and other thinking skills
that get worse over time. The investigators hope to learn more about whether a drug called
memantine can help improve or stabilize (keep the same) memory and other thought processes
in people with epilepsy by blocking a chemical that is released in the brain during
seizures. The investigators also want to see if memantine changes the frequency (how often)
people with epilepsy have seizures. Memantine is currently approved by the United States
Food and Drug Administration (FDA) for treatment of patients with Alzheimer's disease.
Does Memantine Improve Verbal Memory Task Performance in Subjects With Partial Epilepsy and Memory Dysfunction? [Recruiting]
Many patients with epilepsy have memory deficits in the setting of otherwise normal
intelligence. Unfortunately, the treatment options for memory dysfunction in patients with
epilepsy are limited. The investigators are conducting a study to evaluate the effects of
memantine for the treatment of verbal memory dysfunction in subjects with
localization-related seizures. The study involves randomization to memantine therapy or
placebo, with cognitive testing and EEG pre- and post-treatment, as well as after an
open-label memantine treatment phase.
The primary aim of this study is to evaluate the efficacy of memantine for the treatment of
verbal memory dysfunction in subjects with left temporal lobe epilepsy. The investigators
expect that verbal memory task performance will improve in those taking memantine, but not
in those taking a placebo.
The investigators propose that the expected benefit of memantine is specific to verbal
memory in subjects with left temporal lobe seizures, rather than representing an overall
improvement in cognitive function. The investigators expect no improvement on other
cognitive tasks in either the memantine or placebo groups.
The investigators will evaluate whether subjects with left temporal lobe epilepsy and memory
difficulties have self-reported improvement in memory while taking memantine. The
investigators expect improvement of self-rated memory function on the Quality of Life in
Epilepsy Patient Inventory (QOLIE-89) in the memantine group, but no change on this scale in
the placebo group.
Reports of Suspected Namenda (Memantine) Side Effects
Confusional State (7),
Abnormal Behaviour (5),
Movement Disorder (4),
Drug Interaction (4),
OFF Label USE (4),
Thinking Abnormal (3),
Balance Disorder (3), more >>